Pinealon (Glu-Asp-Arg, also known as EDR) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson and colleagues. It belongs to the class of Khavinson peptide bioregulators — short synthetic peptides (2-4 amino acids) designed to regulate gene expression in specific target tissues. Pinealon specifically targets the central nervous system and pineal gland. Research has shown that Pinealon can modulate melatonin synthesis, enhance antioxidant defenses in neural tissue, and protect neurons from age-related damage. The peptide has been shown to regulate expression of genes involved in neuronal survival, synaptic plasticity, and circadian rhythm maintenance. In aging populations, Pinealon has been used to support cognitive function and sleep quality. Like other Khavinson bioregulators, its small size allows it to be taken orally rather than by injection, making it accessible for long-term use.
Key Data
Mechanism of Action
Pinealon modulates gene expression in neurons and pinealocytes by penetrating cell membranes and interacting with DNA regulatory regions. It promotes melatonin synthesis in the pineal gland, enhances antioxidant defense in neural tissue, and supports neurotransmitter balance.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.